Quantcast

Latest Vaccines Stories

2014-07-01 12:28:59

ROCKVILLE, Md., July 1, 2014 /PRNewswire-USNewswire/ -- Serious adverse events resulting from vaccines routinely used in the United States are rare, according to a report funded by the Agency for Healthcare Research and Quality (AHRQ). The report, highlighted in the July issue of Pediatrics, provides the most comprehensive review to date of published studies on the safety of routine vaccines. "The use of vaccines ranks among the most significant public health achievements," said AHRQ...

2014-07-01 08:31:10

- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. In 2011, CureVac and Sanofi Pasteur signed a collaboration and license...

2014-07-01 04:21:50

ZURICH-SCHLIEREN, Switzerland, July 1, 2014 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1 clinical trial of a candidate vaccine to prevent infections caused by Extra-intestinal Pathogenic Escherichia coli (ExPEC), such as urinary tract infections (UTIs). The investigational vaccine is being co-developed by GlycoVaxyn AG and Janssen Pharmaceuticals Inc. (Janssen), one of the Janssen...

2014-06-25 08:29:39

BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a joint notice on reducing and unifying the value added tax (VAT) rate published by the Ministry of Finance of China and State Administration of Taxation of China. The notification...

2014-06-23 04:20:45

Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy...

2014-06-18 16:26:28

Breaking New Ground in a Collective Search for Vaccines against Major Killer Diseases NEW YORK, June 18, 2014 /PRNewswire-USNewswire/ -- New technologies and insights in antigen discovery, genomics and immunological monitoring offer tremendous potential that could be collectively leveraged to speed development of vaccines against major diseases, according to leading scientists who met across specializations to explore creation of a Human Vaccines Project and reported their...

2014-06-18 08:29:32

TITUSVILLE, New Jersey, June 18, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A. VX-787 is an investigational medicine designed to directly inhibit replication of the influenza A virus, including recent H1...

2014-06-17 23:02:39

New research report “Human Papillomavirus Infections Vaccine Pipeline Analysis” drawn up by PNS Pharma is available at MarketPublishers.com. London, UK (PRWEB) June 17, 2014 Human papillomaviruses represent a group of over 150 viruses which are related to each other, with certain types of viruses being able to cause warts (papillomas). There exist only two human papillomavirus vaccines which are currently marketed worldwide. Both these vaccines are prepared with the use of the...

2014-06-17 12:28:42

MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its contract with the Company (contract number HHS0100200900106C) to support development, scale-up and expanded licensure of the Company's influenza vaccines, Flublok® (seasonal) and Panblok® (pandemic). Option Period 2 has a budget of $50.6 million and will run through December 31, 2015. The...

2014-06-17 08:29:10

Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/ -- Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero(®) (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal...


Latest Vaccines Reference Libraries

72_d0e074525de5bb741daf382f8d62213f
2011-04-25 16:38:12

Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium best known for its role in meningitis and other forms of meningococcal disease such as meningococcemia. It is a major cause of morbidity and mortality during childhood in industrialized countries and is responsible for epidemics in Africa and in Asia. In the US there are approximately 2500 to 3500 cases of N. meningitides infections. Children under 5 are at a higher risk as well as people in the sub-Saharan...

45_cbb742ff010fcfbfac5b5b73fd2e0254
2011-02-23 17:23:51

Poliovirus, the causative agent of poliomyelitis and a member of the family of Picornaviridae, is a human enterovirus. It is composed of an RNA genome that is a single-stranded positive-sense RNA. It was first isolate in 1909 and was published in 1981. It is one of the most well characterized viruses and has become a useful model system for understanding the biology of RNA viruses. It infects human cells by binding to an immunoglobulin-like receptor on the cell surface. The three...

More Articles (2 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related